H. Ohgaki, Epidemiology of Brain Tumors, Methods Mol Biol, vol.472, pp.323-342, 2009.
DOI : 10.1007/978-1-60327-492-0_14

R. Stupp, W. Mason, M. Van-den-bent, M. Weller, B. Fisher et al., Radiotherapy plus Concomitant and Adjuvant Temozolomide for Glioblastoma, New England Journal of Medicine, vol.352, issue.10, pp.987-996, 2005.
DOI : 10.1056/NEJMoa043330

M. Kang and S. Kang, Tumorigenesis of Chemotherapeutic Drug-Resistant Cancer Stem-Like Cells in Brain Glioma, Stem Cells and Development, vol.16, issue.5, pp.837-847, 2007.
DOI : 10.1089/scd.2007.0006

F. Pajonk, E. Vlashi, and W. Mcbride, Radiation Resistance of Cancer Stem Cells: The 4 R's of Radiobiology Revisited, STEM CELLS, vol.11, issue.6, pp.639-648, 2010.
DOI : 10.1002/stem.318

A. Daga, C. Bottino, R. Castriconi, R. Gangemi, and S. Ferrini, New Perspectives in Glioma Immunotherapy, Current Pharmaceutical Design, vol.17, issue.23, pp.2439-2467, 2011.
DOI : 10.2174/138161211797249206

C. Wheeler, J. Yu, and K. Black, Cellular immunity in the treatment of brain tumors, Clin Neurosurg, vol.51, pp.132-139, 2004.

J. Wykosky, D. Gibo, C. Stanton, and W. Debinski, EphA2 as a Novel Molecular Marker and Target in Glioblastoma Multiforme, Molecular Cancer Research, vol.3, issue.10, pp.541-551, 2005.
DOI : 10.1158/1541-7786.MCR-05-0056

J. Sampson, A. Heimberger, G. Archer, K. Aldape, A. Friedman et al., Immunologic Escape After Prolonged Progression-Free Survival With Epidermal Growth Factor Receptor Variant III Peptide Vaccination in Patients With Newly Diagnosed Glioblastoma, Journal of Clinical Oncology, vol.28, issue.31, pp.4722-4729, 2010.
DOI : 10.1200/JCO.2010.28.6963

E. Cerato, S. Birkle, J. Portoukalian, A. Mezazigh, J. Chatal et al., ) and Their O-Acetylated Derivatives, Hybridoma, vol.16, issue.4, pp.307-316, 1997.
DOI : 10.1089/hyb.1997.16.307

S. Birkle, G. Zeng, L. Gao, R. Yu, and A. J. , Role of tumor-associated gangliosides in cancer progression, Biochimie, vol.85, issue.3-4, pp.455-463, 2003.
DOI : 10.1016/S0300-9084(03)00006-3

M. Ahmed and N. Cheung, Engineering anti-GD2 monoclonal antibodies for cancer immunotherapy, FEBS Letters, vol.3, issue.2, pp.288-297, 2014.
DOI : 10.1016/j.febslet.2013.11.030

H. Mennel, K. Bosslet, H. Geissel, and B. Bauer, Immunohistochemically visualized localisation of gangliosides Glac2 (GD3) and Gtri2 (GD2) in cells of human intracranial tumors, Experimental and Toxicologic Pathology, vol.52, issue.4, pp.277-285, 2000.
DOI : 10.1016/S0940-2993(00)80046-9

N. Alvarez-rueda, A. Desselle, D. Cochonneau, T. Chaumette, B. Clemenceau et al., A Monoclonal Antibody to O-Acetyl-GD2 Ganglioside and Not to GD2 Shows Potent Anti-Tumor Activity without Peripheral Nervous System Cross-Reactivity, PLoS ONE, vol.38, issue.9, p.25220, 2011.
DOI : 10.1371/journal.pone.0025220.s006

M. Imai, C. Landen, R. Ohta, N. Cheung, and S. Tomlinson, Complement-Mediated Mechanisms in Anti-GD2 Monoclonal Antibody Therapy of Murine Metastatic Cancer, Cancer Research, vol.65, issue.22, pp.10562-10568, 2005.
DOI : 10.1158/0008-5472.CAN-05-1894

Y. Zeng, S. Fest, R. Kunert, H. Katinger, V. Pistoia et al., Anti-neuroblastoma effect of ch14.18 antibody produced in CHO cells is mediated by NK-cells in mice, Molecular Immunology, vol.42, issue.11, pp.1311-1319, 2005.
DOI : 10.1016/j.molimm.2004.12.018

S. Grupp, M. Kalos, D. Barrett, R. Aplenc, D. Porter et al., Chimeric Antigen Receptor???Modified T Cells for Acute Lymphoid Leukemia, New England Journal of Medicine, vol.368, issue.16, pp.1509-1518, 2013.
DOI : 10.1056/NEJMoa1215134

J. Ye and N. Cheung, A novel O-acetylated ganglioside detected by anti-GD2 monoclonal antibodies, International Journal of Cancer, vol.50, issue.2, pp.197-201, 1992.
DOI : 10.1002/ijc.2910500207

D. Cochonneau, M. Terme, A. Michaud, M. Dorvillius, N. Gautier et al., Cell cycle arrest and apoptosis induced by O-acetyl-GD2-specific monoclonal antibody 8B6 inhibits tumor growth in vitro and in vivo, Cancer Letters, vol.333, issue.2, 2013.
DOI : 10.1016/j.canlet.2013.01.032

J. Sampson, B. Choi, L. Sanchez-perez, C. Suryadevara, D. Snyder et al., EGFRvIII mCAR-Modified T-Cell Therapy Cures Mice with Established Intracerebral Glioma and Generates Host Immunity against Tumor-Antigen Loss, Clinical Cancer Research, vol.20, issue.4, pp.972-984, 2014.
DOI : 10.1158/1078-0432.CCR-13-0709

K. Kramer, W. Gerald, B. Kushner, S. Larson, M. Hameed et al., Disialoganglioside G(D2) loss following monoclonal antibody therapy is rare in neuroblastoma, Clin Cancer Res, vol.4, pp.2135-2139, 1998.

F. Denizot and R. Lang, Rapid colorimetric assay for cell growth and survival, Journal of Immunological Methods, vol.89, issue.2, pp.271-277, 1986.
DOI : 10.1016/0022-1759(86)90368-6

R. Wilkinson, A. Lee-macary, D. Davies, D. Snary, and E. Ross, Antibody-dependent cell-mediated cytotoxicity: a flow cytometry-based assay using fluorophores, Journal of Immunological Methods, vol.258, issue.1-2, pp.183-191, 2001.
DOI : 10.1016/S0022-1759(01)00474-4

B. Clemenceau, G. Gallot, R. Vivien, J. Gaschet, M. Campone et al., Long-Term Preservation of Antibody-Dependent Cellular Cytotoxicity (ADCC) of Natural Killer Cells Amplified In Vitro From the Peripheral Blood of Breast Cancer Patients After Chemotherapy, Journal of Immunotherapy, vol.29, issue.1, pp.53-60, 2006.
DOI : 10.1097/01.cji.0000175686.13368.5c

H. Sjogren and I. Hellstrom, Induction of polyoma specific transplantation antigenicity in moloney leukemia cells, Experimental Cell Research, vol.40, issue.1, pp.208-212, 1965.
DOI : 10.1016/0014-4827(65)90319-8

M. Schwartz, A biomathematical approach to clinical tumor growth, Cancer, vol.10, issue.6, pp.1272-1294, 1961.
DOI : 10.1002/1097-0142(196111/12)14:6<1272::AID-CNCR2820140618>3.0.CO;2-H